View Older Stories View More Recent Stories

Nov 4, 2021 10:16AM Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for a Broad Range of Hematologic Diseases
Nov 3, 2021 06:59AM Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases
Oct 27, 2021 06:59AM Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
Oct 25, 2021 06:59AM Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)
Oct 21, 2021 06:59AM Bristol-Myers Squibb (BMY) Receives EU Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarc
Oct 21, 2021 06:59AM Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophagea
Oct 20, 2021 06:59AM The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained
Oct 15, 2021 06:59AM Bristol-Myers Squibb (BMY) Announces Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
Oct 15, 2021 06:59AM Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
Oct 13, 2021 07:00AM Bristol-Myers Squibb (BMY) New Long-term Data from Phase 2 Study Reinforces Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
Oct 13, 2021 06:59AM Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Scleros
Oct 8, 2021 01:50AM Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include Novel Cell Type
Oct 7, 2021 06:59AM Bristol-Myers Squibb (BMY) Phase 2 Study of Deucravacitinib Did Not Meet Primary Endpoint
Oct 7, 2021 06:59AM Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
Oct 1, 2021 07:05AM Bristol Myers Squibb to Hold Investor Event on November 16
Oct 1, 2021 07:00AM Bristol-Myers Squibb (BMY) Announces EMA Application for Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy
Oct 1, 2021 07:00AM European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresecta
Oct 1, 2021 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Sep 30, 2021 09:45AM Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases
Sep 27, 2021 07:07AM Bristol-Myers Squibb (BMY) Announces FDA Accepts Applications for Opdivo + Yervoy and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic ESCC
Sep 27, 2021 07:06AM U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastati
Sep 20, 2021 07:00AM Bristol-Myers Squibb's (BMY) Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Accepted for FDA Priority Review
Sep 20, 2021 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients
Sep 17, 2021 07:00AM Bristol-Myers Squibb (BMY) Announces Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal
Sep 17, 2021 06:59AM Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenoc
Sep 16, 2021 07:00AM Bristol-Myers Squibb (BMY) Five-Year Data from CheckMate -214 Show Opdivo Plus Yervoy Demonstrates Longest Median OS Currently Reported in Phase 3 Trial of Patients with RCC
Sep 16, 2021 06:59AM Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial of Patients with Previously Untreat
Sep 13, 2021 07:05AM According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor Types
Sep 13, 2021 07:00AM Bristol-Myers Squibb (BMY) CheckMate-743 Phase 3 Trial Data Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma
Sep 13, 2021 06:59AM Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma in Phase 3 CheckMate
Sep 10, 2021 08:15PM Bristol Myers Squibb Shares Research Supporting Correlation Between New York Heart Association Functional Class (NYHA class) and Mortality in Obstructive Hypertrophic Cardiomyopathy
Sep 9, 2021 04:16PM Bristol Myers Squibb Announces Dividend
Sep 8, 2021 07:10AM Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021
Sep 8, 2021 07:05AM More than 230 Bristol Myers Squibb Employees Pedal Across the U.S. to Advance Cancer Research in Seventh Annual Coast 2 Coast 4 Cancer Ride
Sep 8, 2021 06:59AM Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-St
Sep 7, 2021 06:59AM Bristol Myers Squibb to Take Part in Morgan Stanley 19th Annual Global Healthcare Conference
Aug 23, 2021 07:01AM Bristol-Myers Squibb (BMY) BLA for Orencia Accepted for Priority Review by FDA for aGvHD
Aug 23, 2021 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)
Aug 20, 2021 11:49AM Bristol-Myers Squibb (BMY) Announces FDA Approves Opdivo for Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma
Aug 20, 2021 11:45AM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma
Aug 19, 2021 09:34AM Bristol-Myers Squibb (BMY) Receives EC Approval for Abecma, the First Anti-BCMA CAR T Cell Therapy for R/R Multiple Myeloma
Aug 19, 2021 09:34AM Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma
Aug 17, 2021 07:00AM Bristol-Myers Squibb (BMY) Announces EMA's Validation of its Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Rec
Aug 17, 2021 06:59AM EMA Validates Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic E
Aug 10, 2021 06:59AM Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow’s Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black T
Aug 3, 2021 07:00AM Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland
Jul 30, 2021 06:59AM Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Fol
Jul 28, 2021 06:59AM Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
Jul 16, 2021 07:00AM Bristol-Myers Squibb (BMY) Provides Update on CheckMate -651 Trial Evaluating Opdivo Plus Yervoy Versus EXTREME Regimen as First-Line Treatment for SCCHN
Jul 16, 2021 06:59AM Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the He
View More Recent Stories View Older Stories